



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 7/48, 7/40		A2	(11) International Publication Number: WO 00/13659								
			(43) International Publication Date: 16 March 2000 (16.03.00)								
(21) International Application Number: PCT/BR99/00072		(81) Designated States: CA, JP, MX, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).									
(22) International Filing Date: 3 September 1999 (03.09.99)											
(30) Priority Data: PI 9803936-9 8 September 1998 (08.09.98) BR		Published <i>Without international search report and to be republished upon receipt of that report.</i>									
(71) Applicant (for all designated States except US): INDÚSTRIA E COMÉRCIO DE COSMÉTICOS NATURA LTDA. [BR/BR]; Rodovia Regis Bittencourt SN - Km 293, CEP-06850 Itapecerica da Serra, SP (BR).											
(72) Inventors; and											
(75) Inventors/Applicants (for US only): ALCANTARA MARTINS ZUCCHETTI, Roberto [BR/BR]; Apartamento 23B, Rua Serra do Japi, 242, Tatuapé, CEP-03309-000 São Paulo, SP (BR). CHITARRA SOUZA, Simoni [BR/BR]; Apartamento 331, Vila Mariana, Rua Estela, 22, CEP-São Paulo, SP (BR). VILLA NOVA SILVA, Luciana [BR/BR]; Rua Américo Alves Pereira Filho, 564, Morumbi, CEP-05688-000 São Paulo, SP (BR).											
(74) Agent: DANNEMANN, SIEMSEN, BIGLER & IPANEMA MOREIRA; Rua Marquês de Olinda, 70, Caixa Postal 2142, Botafogo, CEP-22251-040 Rio de Janeiro, RJ (BR).											
(54) Title: PROCESS AND COMPOSITION FOR ENHANCING THE ACTION OF VITAMIN A ON THE CELLULAR ACTIVITY OF AN INDIVIDUAL, AND USE OF VITAMIN C											
(57) Abstract											
<p>The present invention refers to a process, a composition and the use of Vitamin C for enhancing the action of Vitamin A on the cellular activity of an individual. According to the invention, the association of Vitamin C to Vitamin A will be applied to said individual at a weight ratio ranging from 1:1 to about 10:1.</p>											
<p>- Without exposure to radiation</p> <table border="1"> <thead> <tr> <th>Treatments</th> <th>AC (%)</th> </tr> </thead> <tbody> <tr> <td>PLACEBO</td> <td>~25</td> </tr> <tr> <td>Vitamine A</td> <td>~28</td> </tr> <tr> <td>Vitamine C+Vitamine A</td> <td>~52</td> </tr> </tbody> </table>				Treatments	AC (%)	PLACEBO	~25	Vitamine A	~28	Vitamine C+Vitamine A	~52
Treatments	AC (%)										
PLACEBO	~25										
Vitamine A	~28										
Vitamine C+Vitamine A	~52										
<p>- With exposure to radiation</p> <table border="1"> <thead> <tr> <th>Treatments</th> <th>AC (%)</th> </tr> </thead> <tbody> <tr> <td>PLACEBO</td> <td>~-1.5</td> </tr> <tr> <td>Vitamine A</td> <td>~-13.5</td> </tr> <tr> <td>Vitamine C+Vitamine A</td> <td>~4.5</td> </tr> </tbody> </table>				Treatments	AC (%)	PLACEBO	~-1.5	Vitamine A	~-13.5	Vitamine C+Vitamine A	~4.5
Treatments	AC (%)										
PLACEBO	~-1.5										
Vitamine A	~-13.5										
Vitamine C+Vitamine A	~4.5										

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**Title: "PROCESS AND COMPOSITION FOR ENHANCING THE ACTION OF VITAMIN A
ON THE CELLULAR ACTIVITY OF AN INDIVIDUAL, AND USE OF VITAMIN C"**

5 Field of the Invention

The present invention refers to a process for improving the effects of Vitamin A used in cosmetic compositions in order to enhance the cellular activity of an individual.

Background of the Invention

The compound generically known as Vitamin A comprises retinol and its derivatives, also known as retinoids, in addition to its acidic or aldehyde form, respectively retinoic acid and retinal. Retinoic acid has application in the pharmaceutical and cosmetic industries being, however, prohibited in several countries for cosmetic use due to the adverse effects of irritability which it may cause. Examples of pharmaceutical applications of retinoic acid can be found in the article "Relationships between structure and activity of retinoids", published by Nature, Volume 236, pages 110-113, of September 9, 1996.

In the cosmetic area Vitamin A is usually employed in the form of retinol or some of its retinoids such as retinyl palmitate, and the use of retinol causes various biologic activities, many of which are highly desirable in cosmetic compositions, particularly in those intended to improve the general conditions of the skin of the individual subjected to the topical use thereof. Results achieved by the topical use of Vitamin A are described in passages contained in pages 82 - 119 of the article entitled "Vitamin A Complex", written by Wade Cheng, PhD and Shirley DePetris and published by Skin Inc., March/April 1998.

Moreover, regulation and balance of the epidermal cellular growth through the total synthesis of collagen, among others, such as retention of water in the skin, are also known as effects resulting from the use of Vitamin A in its pure form, called Retinol.

One problem resulting from the use of Vitamin A, either in its pure form or as a derivative, is that, on the one side it promotes the effects of increasing the cellular activity at the level of the dermis and epidermis, accelerating the process of proliferation and differentiation of the keratinocytes and reorganization of the fibers of the dermis (collagen and elastin). But on the other side it must be administered at low doses due to its toxicity. This fact limits the use of Vitamin A and its derivatives to lower contents or requires the utilization of other means that are able to minimize the discomfort of irritation in the skin.

In fact, the use of retinol at low contents is quite common, as shown by several studies, such as the one conducted by the Hamburg Clinic of Experimental Dermatology, in Germany, which discloses tests with low contents of Retinol (0.034%) for men and women with age between 22 and 34 years and which show that such a concentration of retinol could reduce the amount and the deepness of wrinkles. Therefore, this study generally shows the effect of reducing wrinkles by the use of low contents of retinol.

On the other hand, what has been observed is that, even though low concentrations of retinol effectively cause little or no irritation, the results on the skin can remain below the desired levels for the present standards of demand of the consumers in view of the small amount of retinol incorporated in the cosmetic composition and available for its biological action.

In this respect, there have been attempts to obtain compositions of Vitamin A that present effective action and do not cause adverse effects, for instance, the irritation of the skin. As an example, documents US 5516793 and US 5703122 in the name of Avon Products, Inc., are incorporated herein as prior art references. These documents describe a generic association of amounts ranging from 0.5 to 25% by weight of Vitamin C with several irritating active principles, among which Vitamin A is included. This association, however, has the exclusive purpose of reducing irritation of the skin caused by Vitamin A.

It is therefore an objective of the present invention to provide an alternative for the use of Vitamin A at such concentrations that enable an increase in its properties which are beneficial to the skin, without presenting the problems cited above.

Summary of the Invention

The present invention refers to a process for enhancing the action of Vitamin A on the cellular activity of an individual comprising the association of Vitamin C with Vitamin

A, which will be applied to the referred-to individual at a weight ratio ranging from about 1:1 to about 10:1.

In another aspect, the invention refers to a composition for enhancing the action of Vitamin A on the cellular activity of an individual comprising Vitamin C in association with Vitamin A at a weight ratio in the range from about 1:1 to 10:1.

The invention further refers to the use of Vitamin C for enhancing the action of Vitamin A on the cellular activity of an individual.

Brief Description of the Drawings

- Figure 1 shows a graph representing the increase obtained in the cellular activity of a reconstituted skin by the synergistic effect of an association of Vitamin C with Vitamin A according to the invention as compared to the cellular activity of a reconstituted skin treated only with pure Vitamin A.

- Figure 2 shows the synergistic effect on the recuperation and the increase in the cellular activity in reconstituted skin treated with Vitamin A associated with Vitamin C when subjected to ultraviolet irradiation.

Detailed Description of the Invention

After detailed studies the inventors have found that the association of Vitamin C added to compositions containing Vitamin A at a weight ratio ranging from about 1:1 to about 10:1, preferably from about 1:1 to about 5:1, and more preferably from about 1:1 to about 2:1, provides a surprising increase in the cellular activity effects of Vitamin A on an individual.

"Vitamin C" useful for the present invention comprises Vitamin C in its pure form or its derivatives, namely L-ascorbic acid in its molecular form as well as its salts and esters such as ascorbyl phosphate.

As used herein, the expression "an increase in the cellular activity" means the occurrence of a benefit brought about by the increase or improvement at least in one of the situations selected from the maintenance of the cellular condition, the cellular proliferation and the metabolic activity especially in cutaneous cells.

Tests carried out on reconstituted skin show that a treatment of the skin *in vitro* with the association of Vitamin C with Vitamin A according to the present invention promotes an unexpected synergistic increase in the cellular activity of 100% as compared to the cellular activity observed in the same skin treated exclusively with pure Vitamin A or retinol
5 (figure 1).

In the same surprising way, it has been noted that the association of Vitamin C with Vitamin A promotes reconstitution, recuperation and increase in the cellular activity of the skin, even when the individual is subjected to ultraviolet irradiation, which is recognized to cause deleterious effects on the skin and its cells. Tests carried out to this respect show a
10 synergistic effect of reconstitution and increase in the cellular activity of 5% on reconstituted skin treated with Vitamin A associated with Vitamin C when subjected to ultraviolet irradiation (figure 2).

The association of Vitamin C with Vitamin A according to the present invention may be carried out at the moment of the application of these compounds to the individual,
15 but it can also be advantageously formulated as a cosmetic composition containing the two vitamins at a weight ratio ranging from about 1:1 to about 10:1, preferably from about 1:1 to about 5:1, and more preferably from about 1:1 to about 2:1 of Vitamin C to Vitamin A.

According to a preferred embodiment of the invention, said cosmetic composition comprises, by weight, about 0.01 to about 0.9% of Vitamin C and from about 0.008 to
20 about 0.20% of Vitamin A, based on the total weight of the composition. Even more preferably, the composition contains from about 0.02 to about 0.8% by weight of Vitamin C and from about 0.009 to about 0.16% by weight, of Vitamin A and even more preferably the composition contains 0.02 wt.% of Vitamin C and from about 0.009 to about 0.02 wt% Vitamin A, all the percentages based on the total weight of the composition.

25 It is noted that, even at very low concentrations, Vitamin A associated with Vitamin C as defined in the present invention achieves the desired effects of increase in the cellular activity.

The cosmetic compositions containing Vitamin A and Vitamin C at the proportions cited above can also contain other appropriate additives and formulation aids, such as
30 antioxidants for combating free radicals. Among the useful antioxidants, Vitamin E stands out, both in its pure form presented by di- α -tocopherol, and as its derivatives such as dil- α -tocopherol, or 2,6-di-terc-butyl-p-cresol (BHT).

In a particularly preferred way, the cosmetic compositions according to the present invention are formulated in such a manner, that their components are contained in organic vectors such as microspheres and, more particularly, in microspheres or microcapsules containing biologically active material ("Talasferas") such as those defined in US Pat 5,395,620, or in Brazilian patent application PI 9706994-7, filed in the name of this same applicant.

The composition as described above may contain a plurality of said microspheres, in a dispersed form, comprising Vitamin A and, for example, an antioxidant such as Vitamin E, inserted into a first group of microspheres, and Vitamin C inserted into a second group of microspheres. A particularly preferred composition comprises a first group of microspheres containing Vitamin A at an average concentration of 0.014% and Vitamin E at an average concentration of 0.0005% by weight, and a second group of microspheres containing 0.02% by weight of Vitamin C.

Advantageously, in association to the groups of microspheres previously mentioned, such a composition may further contain, in addition to Vitamin A and Vitamin E, cosmetic compounds selected from the group comprising skin structurers, preferably squalan and sphingolipide complexes, skin micronutrients, preferably seaweed extract, sensorial agents, for example, moisteners such as glycerin and hydroxy prolisilan C, emollients such as butylene glycol and cethyl lactate and silicones such as cyclomethicone, solar protection factors such as Parsol 1789 and Eusolex 6300, emulsifiers, preferably Carbopol 1342 associated to trietanolamin and soybean lecitin, thickeners, preferably xanthan gum; sequestrants, preferably EDTA, antioxidants such as BHT and dl- α -tocopherol, fragrances, conservants, water and mixtures thereof.

In one particular embodiment of the present invention, the composition containing Vitamin A and Vitamin C may be in the form of an emulsion and, in this case, the Vitamin C preferably used is L-ascorbic acid stabilized by hydrogen-bridge-forming compounds. Such processes of stabilizing L-ascorbic acid are described in applications PI 9704418-0 and PI 9704728-7, also filed by this same applicant.

As an illustrative example of another possible embodiment of the present invention, the composition is formulated as a gel in which the weight ratio of Vitamin C to Vitamin A is advantageously about 5:1, Vitamin C being present preferably in amounts of about 0.75% and Vitamin C being present in amounts of about 0.16 wt.%, based on the total

weight of the composition. This gel composition may further contain thickeners such as carbopol, fragrances, conservants and water.

Claims

1. A process for enhancing the action of Vitamin A on the cellular activity of an individual, characterized by comprising the association of Vitamin C to Vitamin A, which will be applied to said individual at a weight ratio ranging from about 1:1 to about 10:1 of Vitamin C to Vitamin A.
5
2. A process according to claim 1, characterized in that the weight ratio of Vitamin C to Vitamin A ranges from about 1:1 to about 5:1.
3. A process according to claim 2, characterized in that the weight ratio of Vitamin C to Vitamin A ranges from about 1:1 to about 2:1.
10
4. A process according to any one of claims 1 - 3, characterized in that Vitamin C is L-ascorbic acid stabilized with hydrogen-bridge-forming compounds.
5. A composition for enhancing the action of Vitamin A on the cellular activity of an individual, characterized by comprising Vitamin C in association with Vitamin A at a weight ratio ranging from about 1:1 to about 10:1 of Vitamin C to Vitamin A.
15
6. A composition according to claim 5, characterized in that the weight ratio of Vitamin C to Vitamin A ranges from about 1:1 to about 5:1.
7. A composition according to claim 6, characterized in that the weight ratio of Vitamin C to Vitamin A is of about 5:1, Vitamin C being present at a concentration of about 0.75% and Vitamin A being present at contents of about 0.16%, and in that it optionally contains thickeners, preferably carbopol, fragrances, conservants and water.
20
8. A composition according to claim 6, characterized in that the weight ratio of Vitamin C to Vitamin A ranges from about 1:1 to about 2:1.
9. A composition according to claim 5, characterized in that Vitamin C is present at a concentration of about 0.01% to 0.99% by weight, and Vitamin A is present at a concentration of about 0.008% to 0.20% by weight, based on the total weight of the composition.
25

- 8 -

10. A composition according to claim 8, characterized in that Vitamin C is present at a concentration of about 0.02% to 0.8% by weight, and Vitamin A is present at a concentration of about 0.009% to 0.16% by weight, based on the total weight of the composition.

5 11. A composition according to claim 5, characterized in that Vitamin C is present at a concentration of about 0.02% by weight, and Vitamin A is present at a concentration of about 0.009% to 0.02% by weight, based on the total weight of the composition.

10 12. A composition according to claim 11, characterized in that it contains a plurality of dispersed microspheres, said plurality of microspheres comprising Vitamin A and an antioxidant, preferably Vitamin E, inserted into a first group of microspheres, and Vitamin C inserted into a second group of microspheres.

13. A composition according to claim 12, characterized in that Vitamin C is contained in the second group of microspheres at a concentration of 0.02%.

15 14. A composition according to claim 13, characterized in that it contains a first group of microspheres containing Vitamin A at an average concentration of 0.014% and Vitamin E at an average concentration of 0.0005%, by weight, and cosmetic compounds selected from the group consisting of skin structurers, preferably squalan and sphingolipide complexes, micronutrients of the skin, preferably seaweed extract, sensorial agents, preferably moisteners such as glycerin and hydroxy prolisilan C, emollients such as butylene glycol and cethyl lactate and silicones such as cyclomethicone, solar protection factors such as Parsol 1789 and Eusolex 6300, emulsifiers, preferably Carbopol 1342 associated to trietanolamin and soybean lecithin, thickeners, preferably xanthan gum; sequestrants, preferably EDTA, antioxidants such as BHT and dl- α -tocopherol, fragances, conservants, water and mixtures thereof.

20 25 15. A composition according to any one of claims 5 - 14, characterized in that Vitamin C is L-ascorbic acid stabilized with hydrogen-bridge-forming compounds.

16. Use of Vitamin C, characterized in that it is for enhancing the action of Vitamin A on the cellular activity of an individual.

FIG. 1 - Without exposure to radiation





FIG. 2 - With exposure to radiation



THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : - A61K 7/48, 7/40		A3	(11) International Publication Number: WO 00/13659								
			(43) International Publication Date: 16 March 2000 (16.03.00)								
(21) International Application Number: PCT/BR99/00072		(81) Designated States: CA, JP, MX, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).									
(22) International Filing Date: 3 September 1999 (03.09.99)		Published <i>With international search report.</i>									
(30) Priority Data: PI 9803936-9 8 September 1998 (08.09.98) BR		(88) Date of publication of the international search report: 27 July 2000 (27.07.00)									
(71) Applicant (for all designated States except US): INDÚSTRIA E COMÉRCIO DE COSMÉTICOS NATURA LTDA. [BR/BR]; Rodovia Regis Bittencourt SN - Km 293, CEP-06850 Itapeverica da Serra, SP (BR).											
(72) Inventors; and											
(75) Inventors/Applicants (for US only): ALCANTARA MARTINS ZUCCHETTI, Roberto [BR/BR]; Apartamento 23B, Rua Serra do Japi, 242, Tatuapé, CEP-03309-000 São Paulo, SP (BR). CHITARRA SOUZA, Simoni [BR/BR]; Apartamento 331, Vila Mariana, Rua Estela, 22, CEP-São Paulo, SP (BR). VILLA NOVA SILVA, Luciana [BR/BR]; Rua Américo Alves Pereira Filho, 564, Morumbi, CEP-05688-000 São Paulo, SP (BR).											
(74) Agent: DANNEMANN, SIEMSEN, BIGLER & IPANEMA MOREIRA; Rua Marquês de Olinda, 70, Caixa Postal 2142, Botafogo, CEP-22251-040 Rio de Janeiro, RJ (BR).											
(54) Title: PROCESS AND COMPOSITION FOR ENHANCING THE ACTION OF VITAMIN A ON THE CELLULAR ACTIVITY OF AN INDIVIDUAL, AND USE OF VITAMIN C											
(57) Abstract											
<p>The present invention refers to a process, a composition and the use of Vitamin C for enhancing the action of Vitamin A on the cellular activity of an individual. According to the invention, the association of Vitamin C to Vitamin A will be applied to said individual at a weight ratio ranging from 1:1 to about 10:1.</p>											
<p>- Without exposure to radiation</p> <table border="1"> <caption>Data for 'Without exposure to radiation' chart</caption> <thead> <tr> <th>Treatment</th> <th>AC (%)</th> </tr> </thead> <tbody> <tr> <td>PLACEBO</td> <td>~55</td> </tr> <tr> <td>Vitamine A</td> <td>~25</td> </tr> <tr> <td>Vitamine C+Vitamine A</td> <td>~55</td> </tr> </tbody> </table> <p>Treatments</p>				Treatment	AC (%)	PLACEBO	~55	Vitamine A	~25	Vitamine C+Vitamine A	~55
Treatment	AC (%)										
PLACEBO	~55										
Vitamine A	~25										
Vitamine C+Vitamine A	~55										
<p>- With exposure to radiation</p> <table border="1"> <caption>Data for 'With exposure to radiation' chart</caption> <thead> <tr> <th>Treatment</th> <th>AC (%)</th> </tr> </thead> <tbody> <tr> <td>PLACEBO</td> <td>~0.5</td> </tr> <tr> <td>Vitamine A</td> <td>~-13.5</td> </tr> <tr> <td>Vitamine C+Vitamine A</td> <td>~4.5</td> </tr> </tbody> </table> <p>Treatments</p>				Treatment	AC (%)	PLACEBO	~0.5	Vitamine A	~-13.5	Vitamine C+Vitamine A	~4.5
Treatment	AC (%)										
PLACEBO	~0.5										
Vitamine A	~-13.5										
Vitamine C+Vitamine A	~4.5										

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/BR 99/00072

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K7/48 A61K7/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	US 5 891 470 A (RINALDI MARIE A ET AL) 6 April 1999 (1999-04-06) column 7, line 45 -column 8, line 28 column 9, line 10 - line 30 column 10, line 16 -column 11, line 19; claims ---	1-16
P,X	WO 99 33439 A (ROBERTS RICHARD L ;GREENE JAMES A (US); SHAKLEE CORP (US); SIDDIQU) 8 July 1999 (1999-07-08) page 6, line 3 - line 14; claims 1-10,1624 ---	1-16
P,X	WO 99 24011 A (MURAD HOWARD) 20 May 1999 (1999-05-20) page 9, line 3 - line 15 page 10, line 17 - line 28; claims --- -/-	1-16

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *S* document member of the same patent family

Date of the actual completion of the international search

1 February 2000

Date of mailing of the international search report

25.04.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gerd Strandell/Eö

INTERNATIONAL SEARCH REPORT

Inte tonal Application No
PCT/BR 99/00072

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 781 551 A (ADVANCED POLYMER SYSTEMS INC) 2 July 1997 (1997-07-02) page 2, line 43 -page 3, line-24 page 5, line 1 -page 6, line 21; claims ---	1-16
X	EP 0 229 561 A (MOET HENNESSY RECH) 22 July 1987 (1987-07-22) page 2, line 43 - line 46 page 3, line 38 - line 43 page 11, line 18 - line 31 page 13, line 1 - line 26; claims 1-3,11-14 ---	1-16
X	DATABASE STN INTERNATIONAL "Waging war on wrinkles" retrieved from FILE PROMT, accession no. 1998:413143 XP002900870 abstract & EUROPEAN COSMETIC MARKETS, August 1998 (1998-08), ISSN: 0957-1515 ---	1-16
X	WO 94 09756 A (UNILEVER PLC ;UNILEVER NV (NL)) 11 May 1994 (1994-05-11) page 4, line 24 - line 35 page 23, line 1 - line 25; claims ---	1-16
X	FR 2 612 775 A (THOREL JEAN) 30 September 1988 (1988-09-30) page 3, line 19 - line 23; claims 1-3 ---	1-16
X	US 4 704 280 A (BATES HARRY L) 3 November 1987 (1987-11-03) the whole document ---	1-16
X	DATABASE WPI Section Ch, Week 198706 Derwent Publications Ltd., London, GB; Class B03, AN 1987-040730 XP002900871 & JP 62 000013 A (MIHAMA H), 6 January 1987 (1987-01-06) abstract ---	5-11
X	WO 93 00015 A (KALAMAZOO HOLDINGS INC) 7 January 1993 (1993-01-07) claims 8,9 -----	5-11

INTERNATIONAL SEARCH REPORT

International application No.

PCT/BR 99/00072

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 1-4, 16 all in part because they relate to subject matter not required to be searched by this Authority, namely:
See next sheet
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/BR 99/00072

Claims 1-4, 16 all in part relate to methods of treatment of the human or animal body by surgery or by therapy. See PCT, Rule 39.1(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds compositions.

INTERNATIONAL SEARCH REPORT

make up patent family members

International application No

PCT/BR/99/00072

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
US 5891470	A	06-04-1999	WO	9953904 A		28-10-1999
WO 9933439	A	08-07-1999	US	6015548 A		18-01-2000
			AU	1944599 A		19-07-1999
WO 9924011	A	20-05-1999	AU	1307299 A		31-05-1999
EP 0781551	A	02-07-1997	US	5851538 A		22-12-1998
			AU	697584 B		08-10-1998
			AU	5831096 A		03-07-1997
			CA	2184433 A		30-06-1997
			JP	2960022 B		06-10-1999
			JP	9183722 A		15-07-1997
EP 0229561	A	22-07-1987	FR	2591105 A		12-06-1987
			AT	79027 T		15-08-1992
			CA	1298195 A		31-03-1992
			DE	3686325 A		10-09-1992
			EP	0472225 A		26-02-1992
			ES	2003605 A		01-11-1988
			HK	59493 A		25-06-1993
			JP	2855105 B		10-02-1999
			JP	9110669 A		28-04-1997
			JP	5015689 B		02-03-1993
			JP	62215513 A		22-09-1987
			SG	37493 G		11-06-1993
			US	5034228 A		23-07-1991
WO 9409756	A	11-05-1994	AU	680844 B		14-08-1997
			AU	5420194 A		24-05-1994
			BR	9307375 A		31-08-1999
			DE	69321479 D		12-11-1998
			DE	69321479 T		11-03-1999
			EP	0666735 A		16-08-1995
			ES	2123670 T		16-01-1999
			JP	8502742 T		26-03-1996
			ZA	9308173 A		02-05-1995
FR 2612775	A	30-09-1988		NONE		
US 4704280	A	03-11-1987		NONE		
JP 62000013	A	06-01-1987	JP	2001957 C		20-12-1995
			JP	7017504 B		01-03-1995
WO 9300015	A	07-01-1993	US	5230836 A		27-07-1993
			CA	2071415 A		21-12-1992
			EP	0590029 A		06-04-1994
			JP	6508748 T		06-10-1994
			US	5314686 A		24-05-1994
			US	5290481 A		01-03-1994
			US	5296249 A		22-03-1994

THIS PAGE BLANK (USPTO)